News

Symrise invests in innovative enzymatic technology with sugar alternative experts Bonumose

Symrise AG has signed a minority investment agreement with Bonumose. The early-stage food ingredient manufacturer specializes in the affordable production of delicious, good-for-you rare monosaccharides (alternatives to sucrose) such as tagatose and allulose. With this strategic transaction, Symrise will accelerate growth in its sugar reduction initiatives. The area represents a high-priority focus for the North America region within the Taste, Nutrition & Health segment.

“This exciting investment forges a strategic partnership. It will enhance our flavor and taste balancing technologies with Bonumose’s innovative and economical tagatose and other alternative sweetening solutions. Combining our technologies, will enable us to offer our customers new pathways to sugar reduction and taste balancing solutions. In turn, this will allow them to reduce sugar while optimizing the taste of better-for-you products for their consumers. This applies especially in the beverage and ice-cream categories. Health forms a growing focus category for Symrise. With the support of Bonumose’s enzymatic expertise, we can bring novel and disrupting ingredients to the marketplace together”, said Nick Russell, Senior Vice President – Business Incubation Group, Symrise AG.

Bonumose opened a new R&D facility and manufacturing plant earlier this year. The facility allows for quality, consistent, and economic production of their growing portfolio of sugar alternatives. Bonumose was founded in 2016 as a start-up. It continues to grow thanks to their patented enzymatic technology. This allows for the sustainable bulk production of healthy ingredients from globally-abundant plant material.

Ed Rogers, Bonumose Chief Executive Officer and Co-Founder, said: “We feel enthusiastic about the future and the growth that the investment and partnership with Symrise enables. Now, we are coupling our expertise in tagatose and other naturally-occurring sugar alternatives with the extensive Symrise flavor proficiency and expansive portfolio across multiple platforms in both human food and animal nutrition. This creates the opportunity to offer unique value to customers. The strength of Symrise as an augmented flavor house paired with Bonumose’s patented enzymatic technology will enable cutting edge solutions to sugar reduction.”

Recent News

09/03/2025

Cupron Performance Additives (“Cupron”) announces new distribution relationship with Palmer Holland

Cupron Performance Additives (Cupron) announced today the launch of an exclusive distribution agreement with Palmer Holland, leading North American distributor of specialty additives for the engineered materials marketplace. Palmer Holland will distribute Cupron’s copper-based antimicrobial and anti-odor technologies into plastics, films, foams, and polymeric systems throughout North America. The Cupron line effectively complements Palmer Holland’s

08/26/2025

Activation Capital Names Michael Steele as President and CEO

The Virginia Biotechnology Research Partnership Authority (doing business as Activation Capital) announced today that it has appointed Michael Steele as president and chief executive officer. Steele succeeds Robert Ward, who has served as interim CEO since July 2024 during a period of rapid growth for the life sciences ecosystem development organization. Steele comes to Activation

08/25/2025

Danforth Advisors Acquires PharmaDirections

Danforth Advisors LLC, today announced the acquisition of PharmaDirections, Inc., a full-spectrum development partner to life science companies, expanding its integrated capabilities from discovery through commercialization. Founded in 2003, PharmaDirections was a pioneer of the virtual drug development model. The company brings veteran program leaders and more than 150 specialists to support strategic planning and